Whoops, your site does not have a menu!

Day: August 8, 2018

  1. Home
  2. Archives: August 2018

Amylyx Pharmaceuticals Doses First Patient in Phase II Clinical Trial of AMX0035 for the Treatment of Amyotrophic Lateral Sclerosis

Amylyx Pharmaceuticals Doses First Patient in Phase II Clinical Trial of AMX0035 for the Treatment of Amyotrophic Lateral Sclerosis  

Recent Posts

  • Search for cure against the lethal disease ALS boosted by new investor
  • Orphazyme closes a €14 million Series B Extension
  • Amylyx Pharmaceuticals Receives FDA Orphan Drug Designation for AMX0035 for the Treatment of Amyotrophic Lateral Sclerosis
  • Project ALS and Amylyx Enter Collaboration to Test AMX0035
  • Amylyx closes a $ 5 million Series A Investment